Chimeric antibodies against tick-borne encephalitis virus

Vaccine

Volumn 28, Issue 32, 2010, Pages 5265-5271

  Levanov, Lev N ^a,b   Matveev, Leonid E ^b   Goncharova, Elena P ^a,b   Lebedev, Leonid R ^a   Ryzhikov, Alexander B ^a   Yun, Tatyana E ^a,b   Batanova, Tatyana A ^a   Shvalov, Alexander N ^a   Baykov, Ivan K ^b   Shingarova, Lyudmila N ^c   Kirpichnikov, Michael P ^c   Tikunova, Nina V ^a,b  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^b INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Chimeric antibodies; Neutralization; Tick borne encephalitis virus

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC ANTIBODY 10C2; CHIMERIC ANTIBODY 13D6; GLYCOPROTEIN E; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10C2; MONOCLONAL ANTIBODY 13D6; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 10C2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 13D6; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; GLYCOPROTEIN E, FLAVIVIRUS; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MOUSE; PLASMID; SERODIAGNOSIS; TICK BORNE ENCEPHALITIS VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ENCEPHALITIS VIRUSES, TICK-BORNE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PLASMIDS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRAL ENVELOPE PROTEINS;

EID: 77954951484     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.060     Document Type: Article

References (24)

1. Lindquist L., Vapalahti O. Tick-borne encephalitis. Lancet 2008, 371(9627):1861-1871.
2. Presta L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006, 58(5-6):640-656.
3. Gavilondo J.V., Larrick J.W. Antibody engineering at the millennium. Biotechniques 2000, 29(1):128-145.
4. Laffly E., Sodoyer R. Monoclonal and recombinant antibodies, 30 years after.... Hum Antibodies 2005, 14(1-2):33-55.
5. Tsekhanovskaya N.A., Matveev L.E., Rubin S.G., Karavanov A.S., Pressman E.K. Epitope analysis of tick-borne encephalitis (TBE) complex viruses using monoclonal antibodies to envelope glycoprotein of TBE virus (persulcatus subtype). Virus Res 1993, 30(1):1-16.
6. Mandl C.W. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res 2005, 111(2):161-174.
7. Kipriyanov S.M., Le Gall F. Generation and production of engineered antibodies. Mol Biotechnol 2004, 26(1):39-60.
8. Netesova NA, Belavin PA, Malygin EG, Rukavishnikov MIu. Recombinant plasmid PGSDEI, encoding protein E of tick-borne encephalitis virus and strain Escherichia coli - producer of recombinant protein E of tick-borne encephalitis virus. The patent of Russian Federation. No. 2136754.1999.
9. Wang Z., Raifu M., Howard M., Smith L., Hansen D., Goldsby R., et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity. J Immunol Methods 2000, 233(1-2):167-177.
10. Shingarova L.N., Tikunova N.V., Yun T.E., Chepurnov A.A., Aliev T.K., Batanova T.A., et al. Recombinant full-size human antibody to Ebola virus. Bioorg Khim 2007, 33(6):598-605.
11. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(5259):680-685.
12. Beatty J.D., Beatty B.G., Vlahos W.G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987, 100(1-2):173-179.
13. Protopopova E.V., Khusainova A.D., Konovalova S.N., Loktev V.B. Preparation and study of properties of anti-idiotypic antibodies, carrying hemagglutinating paratopes of tick-borne encephalitis virus on their surface. Vopr Virusol 1996, 41(2):50-53.
14. Dimitrov D.S., Marks J.D. Therapeutic antibodies: current state and future trends - is a paradigm change coming soon?. Methods Mol Biol 2009, 525:1-27.
15. Matveev L.E., Godovikov A.A., Karavanov A.S., Pletnev A.G., Rubin S.G., Semashko I.V., et al. Monoclonal antibodies against tick-borne encephalitis virus glycoprotein: preliminary characterization. Vopr Virusol 1989, 34(6):694-698.
16. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001, 61(12):4750-4755.
17. Goncalvez A.P., Chien C.H., Tubthong K., Gorshkova I., Roll C., Donau O., et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 2008, 82(14):7009-7021.
18. Gould L.H., Sui J., Foellmer H., Oliphant T., Wang T., Ledizet M., et al. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005, 79(23):14606-14613.
19. Itoh K., Inoue K., Hirooka K., Maruyama K., Ohkawa M., Matsui K., et al. Phage display cloning and characterization of monoclonal antibody genes and recombinant Fab fragment against the CD98 oncoprotein. Jpn J Cancer Res 2001, 92(12):1313-1321.
20. Reading S.A., Dimmock N.J. Neutralization of animal virus infectivity by antibody. Arch Virol 2007, 152(6):1047-1059.
21. Li C., Allain J.P. Chimeric monoclonal antibodies to hypervariable region 1 of hepatitis C virus. J Gen Virol 2005, 86(Pt6):1709-1716.
22. Panousis C., Rayzman V.M., Johns T.G., Renner C., Liu Z., Cartwright G., et al. Engineering and characterization of chimeric monoclonal antibody 806 (ch806) for the targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 2005, 92(6):1069-1077.
23. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30(16):1443-1453.
24. Bröker M., Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment. Vaccine 2008, 26(7):863-868.